BGMSPNasdaqWholesale-Durable Goods, NECUS GAAP · USD

Bio Green Med Solution, Inc.

Bio Green Med Solution, Inc. is a U.S.-based pharmaceutical preparations company that appears to be in a transition phase following a transaction involving Fitters Sub. The available filings suggest the company is expanding beyond its legacy operations into new markets and operating environments, which is changing its risk profile and internal control requirements. Based on the disclosed risk factors, the business is now focused not only on operating its core activities but also on integrating acquired operations and managing the resulting compliance, governance, and reporting complexity. The company’s public disclosures are sparse, so the profile is driven mainly by its recent 10-Q risk and accounting commentary rather than a detailed product breakdown.

Ask about the company
Revenue0.0m USD
−100.0 %y/y
Operating profit (EBIT)-8.4m USD
+29.8 %y/y
Net income-3.0m USD
+73.3 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-30-20-10010m USD2020: 0.00 m USD2020: EBIT -11 m USD20202021: 0.00 m USD2021: EBIT -22 m USD20212022: 0.00 m USD2022: EBIT -28 m USD20222023: 0.42 m USD2023: EBIT -25 m USD20232024: 0.04 m USD2024: EBIT -12 m USD20242025: 0.00 m USD2025: EBIT -8.4 m USD20250.00-8.4
RevenueOperating profit (EBIT)

Business

Share of revenue
Pharmaceutical preparations70 %

Medicinal and pharmaceutical products and related preparation activities under the company’s core industry classification.

Acquired operating business20 %

Operations contributed by Fitters Sub that expand the company into additional markets and operating structures.

Compliance and administrative services10 %

Internal compliance, reporting, and control functions required to support regulated operations and integration.

Products

Reported · share of revenue
80.6%15.9%FY2025100 %
  • Fire Safety Equipment80.6 %
  • Safety Aparel15.9 %
  • Project Supply and Installation2.7 %
  • Maintenance and Servicing0.8 %

Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.

Customers

The company’s direct customers are not described in detail in the available excerpts, but its pharmaceutical preparations classification implies sales to healthcare-related buyers, distributors, or other commercial counterparties in regulated channels. The transaction with Fitters Sub suggests the company now serves customers in additional markets that may have different regulatory, licensing, and data-protection expectations. That means customer retention depends not only on product availability but also on the company’s ability to meet compliance, quality, and operational standards across jurisdictions. The filings also indicate that customer relationships could be affected if integration problems or security incidents disrupt service or reduce trust.

Healthcare and regulated-market buyers

Buy pharmaceutical preparations and related products that must meet quality, compliance, and documentation requirements.

Acquired-market customers

Customers served through Fitters Sub in markets different from the legacy business, where local rules and operating practices matter.

Commercial intermediaries and distributors

Buy or distribute products and depend on consistent supply, regulatory compliance, and operational continuity.

Strategy

The company’s near-term strategy appears centered on integrating Fitters Sub and realizing the expected benefits of the transaction. Management emphasizes the need to align systems, controls, personnel, and operating processes across the combined enterprise, which suggests integration is the main operational priority. A second strategic objective is to preserve customer and supplier relationships while expanding into markets that differ from the legacy business. Longer term, the company will need to prove that the transaction creates durable scale and does not overwhelm internal controls or management attention.

Post-transaction integrationShort term

The company needs to combine systems, processes, and teams to realize the expected benefits of the acquisition.

Internal control strengtheningShort term

A larger and more complex business increases the risk of reporting errors and regulatory scrutiny if controls are weak.

Market expansion and synergy captureMedium term

The transaction is intended to broaden the company’s operating footprint and create operational or financial synergies over time.

Geography

The company is headquartered in the United States, but the recent transaction indicates exposure to additional jurisdictions through Fitters Sub. Management explicitly notes that the combined company may face different demand cycles, pricing dynamics, supply chain constraints, foreign exchange rates, and geopolitical risks than the legacy business. The filings do not provide a country-by-country revenue split, so the geographic profile cannot be quantified from the available excerpts. What is clear is that the business is becoming more geographically complex, which increases compliance and integration burden.

Risks

The most important company-specific risk is execution risk around the Fitters Sub transaction, including integration failure, loss of key personnel, and inability to realize expected synergies. Management also highlights increased exposure to regulatory, compliance, cybersecurity, and data privacy risks because the acquired business operates in jurisdictions and industries where the company has limited prior experience. The company further warns that internal control over financial reporting has become more complex, raising the risk of errors, misstatements, and regulatory scrutiny. More generally, a pharmaceutical preparations business faces industry risks tied to regulation, product quality, supply chain disruption, and customer concentration, all of which can be amplified when operations span multiple markets.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Failure to integrate Fitters Sub successfully1Regulatory and compliance risk in new jurisdictions2Cybersecurity and data privacy incidents3Internal control over financial reporting weaknesses4Unknown or contingent liabilities from acquisition5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Failure to integrate Fitters Sub successfullyImpact: HighLikelihood: Medium

    The company says the transaction may not deliver expected benefits if systems, personnel, and operations are not aligned effectively.

    Exposure: Combined company operations and management attention

  2. Regulatory and compliance risk in new jurisdictionsImpact: HighLikelihood: Medium

    Fitters Sub operates in markets with different or more stringent rules, increasing the chance of non-compliance and penalties.

    ExposureLicensingIndustry standardsData protectionLocal regulation
  3. Cybersecurity and data privacy incidentsImpact: HighLikelihood: Medium

    Management explicitly notes higher exposure to security and privacy obligations and the potential for breaches or incidents.

    ExposureCustomer dataSystemsCompliance programs
  4. Internal control over financial reporting weaknessesImpact: HighLikelihood: Medium

    Integrating a new business increases the complexity of controls and the risk of errors, restatements, or audit issues.

    Exposure: Financial reporting and disclosure controls

  5. Unknown or contingent liabilities from acquisitionImpact: MediumLikelihood: Medium

    The acquired business may carry tax, legal, environmental, employment, or warranty liabilities not fully identified in due diligence.

    Exposure: Balance sheet reserves and future cash outflows

Accounting

Judgemental items
Purchase accounting and fair value measurement

The acquisition method requires judgment in valuing acquired assets and liabilities, which can materially affect reported earnings and balance sheet values.

Impact: May create amortization expense, remeasurement gains/losses, and balance sheet volatility

Goodwill and intangible asset impairment

If the acquired business underperforms or macro conditions worsen, the company may need to record impairment charges.

Impact: Could materially reduce reported earnings and equity

Contingent liabilities and reserves

Undiscovered tax, legal, environmental, or employment obligations may require future accruals or cash payments.

Impact: Can increase expenses and reduce cash flow

Internal control over financial reporting

Combining different systems and control environments raises the risk of misstatements and delayed reporting.

Impact: Could affect reliability of reported results and investor confidence

Similar listed companies

Publicly listed companies with a comparable business focus.

Green Planet Bio Engineering Co. Ltd.

GPLB · Biological Products, (No Diagnostic Substances)

Bioxytran, Inc

BIXT · Pharmaceutical Preparations

BioScience Health Innovations, Inc.

BHIC · Services-Computer Processing & Data Preparation

Greenland Mines Ltd

GRMLW · Biological Products, (No Diagnostic Substances)

Bio Essence Corp

BIOE · Pharmaceutical Preparations

Sino Green Land Corp.

SGLA · Wholesale-Misc Durable Goods

Last updated: 24/09/2026

Bio Green Med Solution, Inc. (Nasdaq) – Wholesale-Durable Goods, NEC | Financial Analysis – Clarifo